Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
NCT07473323Phase 1Recruiting
- Sponsor
- Mediar Therapeutics
- Start
- May 2026
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in diabetic kidney disease (DKD) comparing MTX-439 with Placebo (2 arms). Primary endpoints: Incidence of Dose-Limiting Toxicities at Day 113, Incidence of Treatment-Emergent Adverse Events at Day 113 and 13 more. Started May 2026; status: recruiting.
02
Drugs
MTX-439
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT07473323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07473323.